Carlsbad, CA — August 25, 2025 — Leads & Copy — Palisade Bio, Inc. (Nasdaq: PALI) has released a Virtual Investor KOL Connect segment featuring Dr. Brian G. Feagan, MD, FRCPC, a leading expert in Fibrostenotic Crohn’s Disease (FSCD) and Inflammatory Bowel Diseases (IBD).
The segment provides insight into the need for more effective treatment options for FSCD and how PALI-2108 may become a leader in IBD therapeutics. Dr. Feagan, a Professor of Medicine, Epidemiology & Biostatistics at Western University, a gastroenterologist at London Health Sciences Centre, and Senior Scientific Director at Alimentiv, Inc., discussed FSCD and the challenges with current therapies, highlighting the need for therapeutics that address both inflammation and the fibrotic process. He also provided his perspective on PALI-2108’s novel approach and its potential impact on the treatment landscape. PALI-2108’s localized approach is designed to reduce class-associated side effects while preserving anti-inflammatory and anti-fibrotic activity.
The Virtual Investor KOL Connect segment featuring Palisade Bio is available here.
For more information about PALI-2108 and the Company’s development plans, visit www.palisadebio.com.
Contact: Jenene Thomas, JTC Team, LLC, 908-824-0775, PALI@jtcir.com
Source: Palisade Bio
